Pleiotropic effects of ezetimibe/simvastatin vs. high dose simvastatin

Imagem de Miniatura
Arquivos
art_PESARO_Pleiotropic_effects_of_ezetimibe_simvastatin_vs_high_dose_2012.PDF (241.09 KB)
Citações na Scopus
42
Tipo de produção
article
Data de publicação
2012
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER IRELAND LTD
Autores
CAVALCANTI, Alexandre B.
CAMPOS, Alexandre H.
LEMOS, James A. de
Citação
INTERNATIONAL JOURNAL OF CARDIOLOGY, v.158, n.3, p.400-404, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: In the setting of stable coronary artery disease (CAD), it is not known if the pleiotropic effects of cholesterol reduction differ between combined ezetimibe/simvastatin and high-dose simvastatin alone. Objective: We sought to compare the anti-inflammatory and antiplatelet effects of ezetimibe 10 mg/simvastatin 20 mg (E10/S20) with simvastatin 80 mg (S80). Methods and results: CAD patients (n = 83, 63 +/- 9 years, 57% men) receiving S20, were randomly allocated to receive E10/S20 or S80, for 6 weeks. Lipids, inflammatory markers (C-reactive protein, interleukin-6, monocyte chemoattractant protein-1, soluble CD40 ligand and oxidized LDL), and platelet aggregation (platelet function analyzer [PFA]-100) changes were determined. Baseline lipids, inflammatory markers and PFA-100 were similar between groups. After treatment, E10/S20 and S80 patients presented, respectively: (1) similar reduction in LDL-C (29 +/- 13% vs. 28 +/- 30%, p = 0.46), apo-B (18 +/- 17% vs. 22 +/- 15%, p = 0.22) and oxidized LDL (15 +/- 33% vs. 18 +/- 47%, p = 0.30); (2) no changes in inflammatory markers; and, (3) a higher increase of the PFA-100 with E10/S20 than with S80 (27 +/- 43% vs. 8 +/- 33%, p = 0.02). Conclusions: These data suggest that among stable CAD patients treated with S20, (1) both E10/S20 and S80 were equally effective in further reducing LDL-C; (2) neither treatment had any further significant anti-inflammatory effects; and (3) E10/S20 was more effective than S80 in inhibiting platelet aggregation. Thus, despite similar lipid lowering and doses 4x less of simvastatin, E10/S20 induced a greater platelet inhibitory effect than S80.
Palavras-chave
Inflammation, Statins
URI
https://observatorio.fm.usp.br/handle/OPI/528
Referências
  1. Ascer E, 2004, ATHEROSCLEROSIS, V177, P161, DOI 10.1016/j.atherosclerosis.2004.07.003
  2. Azar RR, 2010, AM J CARDIOL, V106, P193, DOI 10.1016/j.amjcard.2010.03.016
  3. Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1
  4. Blanco-Colio LM, 2007, AM HEART J, V153, P881, DOI 10.1016/j.ahj.2007.02.029
  5. Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583
  6. Ceriello A, 2005, CIRCULATION, V111, P2518, DOI 10.1161/01.CIR.0000165070.46111.9F
  7. de Lemos JA, 2007, J AM COLL CARDIOL, V50, P2117, DOI 10.1016/j.jacc.2007.06.057
  8. Fenton J. W. II, 2005, Current Drug Targets - Cardiovascular & Haematological Disorders, V5, P115, DOI 10.2174/1568006043586189
  9. Fleg JL, 2008, J AM COLL CARDIOL, V52, P2198, DOI 10.1016/j.jacc.2008.10.031
  10. Glynn RJ, 2009, NEW ENGL J MED, V360, P1851, DOI 10.1056/NEJMoa0900241
  11. Grundy Scott M, 2004, J Am Coll Cardiol, V44, P720, DOI 10.1016/j.jacc.2004.07.001
  12. Gurbel PA, 2007, CIRCULATION, V115, P3156, DOI 10.1161/CIRCULATIONAHA.106.675587
  13. Collins R, 2002, LANCET, V360, P7
  14. Hussein O, 2008, BRIT J CLIN PHARMACO, V65, P637, DOI 10.1111/j.1365-2125.2007.03080.x
  15. Karepov VG, 2006, INT J STROKE S1, V1, P72
  16. Kinlay S, 2007, J AM COLL CARDIOL, V49, P2003, DOI 10.1016/j.jacc.2007.01.083
  17. KOLLER E, 1986, FEBS LETT, V200, P97, DOI 10.1016/0014-5793(86)80518-X
  18. Kosoglou T, 2005, CLIN PHARMACOKINET, V44, P467, DOI 10.2165/00003088-200544050-00002
  19. Kunes J, 2000, LIFE SCI, V67, P959, DOI 10.1016/S0024-3205(00)00691-3
  20. Lordkipanidze M, 2007, EUR HEART J, V28, P1702, DOI 10.1093/eurheartj/ehm226
  21. Malmstrom RE, 2009, THROMB HAEMOSTASIS, V101, P157, DOI 10.1160/TH08-06-0385
  22. Mammen EF, 1998, SEMIN THROMB HEMOST, V24, P195, DOI 10.1055/s-2007-995840
  23. Piorkowski M, 2007, J AM COLL CARDIOL, V49, P1035, DOI 10.1016/j.jacc.2006.10.064
  24. Puccetti Luca, 2005, Current Drug Targets - Cardiovascular & Haematological Disorders, V5, P121, DOI 10.2174/1568006043586161
  25. Relou IAM, 2003, CELL MOL LIFE SCI, V60, P961, DOI 10.1007/s00018-003-2249-y
  26. Ridker PM, 2005, NEW ENGL J MED, V352, P20, DOI 10.1056/NEJMoa042378
  27. Sager PT, 2003, AM J CARDIOL, V92, P1414, DOI 10.1016/j.amjcard.2003.08.048
  28. Sestito A, 1999, Cardiologia, V44, P661
  29. Shewan LG, 2010, INT J CARDIOL, V144, P1, DOI 10.1016/j.ijcard.2010.07.030
  30. Tirnaksiz E, 2009, J THROMB THROMBOLYS, V27, P24, DOI 10.1007/s11239-007-0154-1
  31. Vlasova II, 2000, PLATELETS, V11, P406, DOI 10.1080/09537100020000157

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Carregar mais